Role of basiliximab in the prevention of acute cellular rejection in adult to adult living-related liver transplantation: a single center experience by Gruttadauria, S et al.
Biologics: Targets & Therapy 2007:1(1) 69–73
© 2007 Dove Medical Press Limited.  All rights reserved
69
CASE STUDY
Role of basiliximab in the prevention of acute 
cellular rejection in adult to adult living-related 
liver transplantation: a single center experience
S Gruttadauria 
L Mandalà 
D Biondo 
M Spampinato 
V Lamonaca 
R Volpes 
G Vizzini 
JW Marsh 
A Marcos
B Gridelli
Istituto Mediterraneo Trapianti 
e Terapie ad Alta Specializzazione 
(IsMeTT), Italy, Palermo, Italy; 
University of Pittsburgh Medical 
Center (UPMC) Italy, Palermo, Italy
Correspondence: Salvatore Gruttadauria 
ISMETT (Istituto Mediterraneo
Trapianti e Terapie ad Alta 
Specializzazione)
Via E. Tricomi N. 1, 90127 Palermo, Italy
Tel +39 0912 192111
Fax +39 0912 192400
Email sgruttadauria@ismett.edu
Abstract: We report our single center experience with the use of basiliximab, a 
chimeric monoclonal antibody directed against the alpha chain of the interleukin-2 (IL-2) 
receptor (CD25), in combination with a steroid- and tacrolimus-based regimen in adult to adult 
living-related liver transplantation (ALRLT). Sixty consecutive ALRLTs were analyzed. All 
patients received two 20-mg doses of basiliximab (days 0 and 4 after transplantation) followed 
by tacrolimus (0.15 mg/kg/day; 10–15 ng/mL target trough levels) and a dose regimen of steroids 
(starting with 20 mg iv, switched to po as soon as the patient was able to eat, and weaned off 
within 1–2 months). Follow-up ranged from 6 to 1699.4 days after transplantation (mean 517.5 
days, SD ± 413.4; median 424 days). Of the recipients, 95% remained rejection-free during 
follow-up, with an actuarial rejection-free probability of 96.61% within 3 months. Three patients 
had episodes of biopsy-proven acute cellular rejection (ACR). Actuarial patient and graft survival 
rates at 3 years were 82.09% and 75.61%. Six patients (10%) experienced sepsis. There was no 
evidence of cytomegalovirus infections or side-effects related to the basiliximab. We found zero 
de novo malignancy, although we observed 5 patients with metastatic spread of their primary 
malignancy during the follow-up. Basiliximab in association with tacrolimus and steroids is 
effective in reducing episodes of ACR and increasing ACR-free survival after ALRLT.
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Introduction
Living-related liver transplantation (LRLT) was initially performed successfully in 
the pediatric population (Otte 2002), and then proposed as one of the most effective 
measures to counteract organ-donor shortage for adults. LRLT evolved naturally from 
other surgical procedures, namely reduced-size liver transplantation and split-liver 
transplantation (Heffron et al 1998), based on the segmental anatomy of the liver and 
on its peculiar capacity to regenerate. However, there has been ongoing debate over 
the ethics of posing a potential risk to the donor (Marcos 2000), and some uncertainty 
as to recipient outcomes (Gruttadauria et al 2005a). Since adult to adult living-related 
liver transplantation (ALRLT) ﬁ  rst became as a valuable therapeutic option for end-
stage liver diseases, the immunosuppressive protocols available to reduce the risk 
of acute cellular rejection (ACR) have been continually changing. The transplanted 
liver is generally considered immunologically privileged, regardless of the source 
of donation (from living or deceased donor), with low incidences of graft loss due to 
acute or chronic rejection. However, despite advances in immunosuppression, ACR 
remains an important risk factor. Immunosuppressive therapy in ALRLT is usually 
aimed at achieving early corticosteroid weaning and maintenance with low-dose 
calcineurin inhibitor, at minimizing potential deleterious pharmaceutical side-effects, 
and at trying to induce a potential mechanism of tolerance (Ringe et al 2005). With the 
advent of newer immunosuppressive agents, including interleukin-2 receptor antibody Biologics: Targets & Therapy 2007:1(1) 70
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(IL-2Rab) (Brennan et al 2006), and sirolimus, early steroid 
reduction or withdrawal in liver transplant recipients appears 
to be practical. Monoclonal antibodies (MAb) speciﬁ  cally 
targeting the interleukin-2 (IL-2) receptor were developed 
to reduce these adverse effects (Moser 2003). IL-2 receptor 
antibodies include the chimeric IL-2 receptor antibody basi-
liximab (Simulect) (Nashan et al 1997; Kahan et al 1999; 
Adu et al 2003; Ponticelli et al 2001) and the humanized IL-2 
receptor antibody daclizumab (Zenapax®). Both are directed 
against the α-chain (CD25), which is expressed on activated 
T cells. As inhibitors of IL-2 binding, they prevent ACR by 
inhibiting IL-2-driven T-cell proliferation.
Herein we report our single center experience with the 
use of basiliximab as part of the immunosuppressive regi-
men in our group of ALRLT recipients.
Materials and methods
From January 2002 to December 2006 we performed 
60 ALRLTs. The number of cases per year has been 
progressively increasing, with a peak reached in 2006, 
when 24 liver transplants out of a total of 102 were ALRLT. 
All recipient and donor demographics are presented 
in Table 1, and primary indications to transplantation 
are listed in Table 2. Donors always had genetic or 
emotional relationships with the recipients; 33 couples 
were ABO identical, and 27 compatible. Donor liver 
resections resulted in 58 right hepatectomies and two left 
hepatectomies; graft implantation was performed with the 
preservation of the recipient inferior vena cava, and in 
50 cases with the use of veno-venous bypass. 
The immunosuppressive protocol included 20 mg 
basiliximab (Simulect®) in association with 500 mg 
methylprednisolone at the time of liver reperfusion; both 
were given by iv bolus. An additional 20 mg dose of 
basiliximab was administered by iv bolus on day 4 after 
transplantation. Tacrolimus (Prograf®) was administered 
at 0.15 mg/kg/day by mouth or through the nasogastric 
tube within 24 hours after the transplant, and adjusted 
to achieve trough levels in the range of 8–10 ng/mL. At 
30 days post-transplantation, the target trough level was 
reduced to 5–7 ng/mL. Corticosteroids were administered 
in a standard rapid taper regimen for the first month: 
methylprednisolone at 50 mg iv every 6 hours on day 1; 
40 mg iv every 6 hours on day 2; 30 mg iv every 6 hours 
on day 3; 20 mg iv every 6 hours on day 4; and 20 mg iv 
every 12 hours on day 5; and 20 mg prednisone by mouth 
or through the nasogastric tube on days 6–15; then 10 
mg/day for 1 week; and 5 mg/day for 1 additional week. 
After the ﬁ  rst year, we prescribed only methylprednisone 
20 mg iv for the ﬁ  rst 2–3 days and then 20 mg prednisone 
by mouth, slowly decreasing and weaning from corticoste-
roids within 1–2 months. In the case of ACR, depending 
Table 1 Demographic characteristics of 60 living donors and recipients
   Donor     Recipient 
Characteristics  n  Mean ± SD or percent  n  Mean ± SD or percent
Age      32.26 ± 9.44    52.65 ± 12.23
 Range    [18;53]    [18;67]
 Classes       
 0–20  5  8.33%  2  3.33%
 21–40  43  71.67%  6  10.00%
 41–60  12  20.00%  37  61.67%
 61–80  0  0.00%  15  25.00%
Sex          
 Male  28  46.67%  20  33.33
 Female  32  53.33%  40  66.67
Height (cm)    169.10 ± 8.94    167.55 ± 9.41
Weight (kg)    68.53 ± 11.12    69.98 ± 12.74
Donor to recipient relationship        
  Biologically related  52  86.67%    
  Sibling  7  11.67%     
  Child  41  68.33%     
  Parent  4  6.67%     
  Not biologically related  8  13.33%    
  Spouse  3  5.00%     
  Other  nonbiological  5  8.33%       Biologics: Targets & Therapy 2007:1(1) 71
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on the gravity of the rejection, the protocol comprised a 
bolus administration of 500 mg methylprednisolone to be 
repeated 3 times. Simultaneously, the tacrolimus target 
level was increased to 8–10 ng/mL. Cytomegalovirus 
(CMV) pp65 antigenemia-guided pre-emptive therapy 
was used for CMV prophylaxis; surveillance for CMV 
antigenemia was performed at weeks 2, 4, 6, 8, 12, and 16 
post-transplantation. If positive, oral ganciclovir was used 
for 6 weeks (Singh et al 2000). Follow-up ranged from 6 
to 1699.4 days after transplantation (mean 517.5 days, SD 
± 413.4, median 424 days). Parameters evaluated included 
graft failure, need and indication for retransplantation, and 
number of retransplants. The diagnosis of ACR was always 
biopsy proven.
Statistical analysis
Continuous variables are presented as the mean values ± SD, 
and categorical variables as rates. For survival, the Kaplan-Meier 
method was used. Patient survival/death, ACR-free time, and 
infection rate also were measured. The analyses were performed 
using SPSS (SPSS Inc., Chicago, Ill, United States).
Results
The majority of patients experienced a successful outcome. 
Actuarial patient survival rate at 3 years was 82.09%, while 
graft survival rate was 75.61% (Figure 1). Of all patients, 
95% were free of ACR episodes during the follow-up period, 
with a rejection-free probability of 96.61% within 3 months; 
OKT3 or other antibody therapy was never required to treat 
rejection. Table 3 synthesizes morbidity and mortality in 
the recipient population. There were 10 deaths: 6 due to 
sepsis (60%) and 4 due to recurrence of neoplastic disease 
(40%). Three patients had ACR episodes: 2 within 3 months; 
1 within 6 months. Retransplantation was necessary in 6 
patients (10%): 5 due to hepatic artery thrombosis and 1 
due to graft malfunction.
Four patients developed a CMV infection: 3 within 
3 months, 1 within 6 months. We found zero de novo 
malignancy, but we observed 5 patients (8.33%) with 
progression of their neoplastic disease at different stages 
after transplantation.
Basiliximab was well tolerated by all patients. No 
acute side-effects were noted, including acute infusion 
reactions. No patients or grafts were lost due to acute or 
chronic rejection.
Discussion
This single center experience here reported shows that 
basiliximab in a tacrolimus-based immunosuppression 
regimen is well tolerated and effective in both reducing 
episodes of ACR and increasing ACR-free survival after 
LRLT.
We believe that there are two important advantages of 
this protocol; the ﬁ  rst is achieving early steroid reduction. 
Previous reports have shown that early reduction or 
elimination of corticosteroids can significantly reduce 
the incidence of many complications in liver transplant 
recipients. Moreover, corticosteroids are frequently 
implicated in the acceleration of viral replication and 
recurrence after liver transplantation (Marino et al 2004).
In our series, although more than 50% of the patients 
transplanted had primary diagnosis end stage liver disease 
secondary to hepatitis C virus infection, only 9 patients had 
recurrence of their primary disease and are all undergoing 
antiviral treatment.
Corticosteroids are associated with a number of hemo-
dynamic and metabolic effects which may generate risk 
factors that favor cardiovascular diseases. Among these 
risk factors are hypertension, diabetes mellitus, and hyper-
lipidemia. Corticosteroids are also associated with cataract 
Table 2 Primary indication to transplantation
Characteristics   n  Percent
Diagnosis 
 HCC+HCV  22  36.67
 HCV  17  28.33
 HBV  3  5.00
 PBC  2  3.33
 Cystic  ﬁ  brosis  2  3.33
 HCC+alcohol  2  3.33
 HBV-HCV  1  1.67
 HCC+HBV  1  1.67
 Calcinoid  mets  1  1.67
 HCC+HCV+HBV  1  1.67
 Alcohol  1  1.67
 HBV-HDV  1  1.67
 HCC+NASH  1  1.67
 HBV-HCC  1  1.67
 PSC  1  1.67
 Cryptogenic  1  1.67
 OTC  deﬁ  ciency  1  1.67
 Biliary  atresia  1  1.67
MELD Score  
 8–10  6  10.00
 11–20  25  41.67
 21–30  27  45.00
 31–40  1  1.67
 Missing  1  1.67
Abbreviations: HBC, hepatitis B core ; HBV, hepatitis B virus; HCC, hepato 
cellular carcinoma; PBC, primary biliary cirrhosis; NASH, non-alcoholic steatohepa-
titis; OTC, ornithine transcarbamylase; PSC, primary sclerosing cholangitis; MELD, 
Model End-Stage Liver Disease.Biologics: Targets & Therapy 2007:1(1) 72
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formation, aseptic necrosis of bone, osteoporosis, and 
cosmetic alterations such as acne vulgaris and obesity.
The second advantage lies in trying to create a tolero-
genic protocol by using a chimeric monoclonal antibody. 
In this report the use of basiliximab in ALRLT treated 
with tacrolimus-based immunosuppression decreased ACR 
while avoiding the serious adverse effects associated with 
broad T-cell depletion. 
However, MAb also may be beneﬁ  cial to patients when 
used in calcineurin inhibitor-sparing regimens. The improved 
rates of ACR and patient survival without signiﬁ  cant adverse 
events seen in our group of recipients support the further 
investigation of basiliximab as an agent that facilitates the 
withdrawal of cyclosporine or tacrolimus over time. 
We previously reported that this drug does not increase 
the incidence of opportunistic infections or malignan-
cies above baseline in patients treated with conventional 
calcineurin inhibitor-based immunosuppression, with a 
reasonable cost-beneﬁ  t ratio (Gruttadauria et al 2005b, 
2006).
Antibody induction is a means of reducing the risk 
of ACR in the early post-transplantation period, while 
simultaneously attempting to avoid the long-term use of 
corticosteroids. The immunosuppressive protocol here 
reported was based on our previous experience with pa-
tients who received cadaveric liver donations; thus this 
series represents a learning curve reflecting surgical and 
clinical management improvements.
Table 3 Morbidity and mortality in the ALRLT recipients
    90 days  1 year  After 1 year  Total
   0–90  91–365   
All deaths    4 3  3  10
Cause of death         
  Recurrence of neoplastic disease    0  1  3  4
 Sepsis    4  2  0  6
Retransplants (10.00%)   6  0  0  6
Cause of retransplant         
  Hepatic artery thrombosis    5  0  0  5
 Multifactorial    1  0  0  1
ACR   2  1  0  3
CMV infection   3  1  0  4
Abbreviations: ACR, albumin-to-creatinine ratio;  ALRT, adult living-related liver transplantation; CMV, cytomegalovirus.
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Figure 1 Actuarial survival curve of the patients and grafts in the 60 living-related liver transplants performed (3 years).Biologics: Targets & Therapy 2007:1(1) 73
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